Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?

Cancer

Volumn 85, Issue 11, 1999, Pages 2391-2399

  Ostmeier, Hermann ^a   Fuchs, Blandine ^a   Otto, Friedrich ^a   Mawick, Reinhard ^a   Lippold, Andrea ^a   Krieg, Volker ^b   Suter, Ludwig ^a  

^a Fachklinik Hornheide   (Germany)

^b Epidemiologisches Krebsregister NRW   (Germany)

Author keywords

Age; Breslow's thickness; Gender; Immunohistochemical markers; Localization; Localized melanoma; Mitoses; Multivariate Cox regression analysis; Prognostic factors; Ulceration

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; TUMOR ANTIGEN;

AGE; ARTICLE; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS RATE; MODEL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; THICKNESS; TUMOR LOCALIZATION; ULCER;

AGED; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MITOSIS; MULTIVARIATE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033152462     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I     Document Type: Article

References (64)

1. Bröcker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984;82: 244-7.
2. Bröcker EB, Suter L, Brüggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985;36:29-35.
3. Suter L, Brüggen J, Bröcker EB, Sorg C. A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int J Cancer 1985;35:787-91.
4. Holzmann B, Bröcker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmüller G, et al. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-71.
5. Ostmeier H, Suter L. The Ki-67 antigen in primary human melanomas - its relationship to mitotic rate and tumor thickness and its stability. Arch Dermatol Res 1989;281: 173-7.
6. Carrel S, Doré J-F, Ruiter DJ, Prade M, Lejeune F, Kleeberg UR, et al. (on behalf of the EORTC Malignant Melanoma Co-Operative Group). The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer 1991;48:836-47.
7. Colloby PS, West KP, Fletcher A. Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology 1992;20:411-6.
8. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki BM. Tumor progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 1993;170:429-34.
9. Si Z, Hersey P. Immunohistological examination of the relationship between metastatic potential and expression of adhesion molecules and "selectins" on melanoma cells. Pathology (Australia) 1994;26:6-15.
10. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105:22-6.
11. Van den Oord JJ, Maes A, Stas M, Nuyts J, Battochio S, Kasran A, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996;149: 1953-61.
12. De Wit PE, van Muijen GN, de Waal RM, Ruiter DJ. Pathology of malignant melanoma, including new markers and techniques in diagnosis and prognosis. Curr Opin Oncol 1996;8:143-51.
13. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996;63:169-73.
14. Boni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-8.
15. Dietrich A, Tanczos E, Vanscheidt W, Schöpf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997;33:926-30.
16. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, di Fillipo F, et al. Clinical significance of alpha (v) beta 3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-60.
17. Cochran AJ. Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res 1997; 10:162-7.
18. Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and non exposed sites. Cancer 1998.82:309-16.
19. Doré J-F, Maisonneuve P, Cattaruzza MS, Autier P, Cochran AJ, Boyle P. A molecular epidemiological approach to the study of expression of a metastasis marker in primary melanomas and its correlation with individual patient's risk of recurrence or metastasis. Melanoma Res 1997;7(Suppl): S121-5.
20. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978;114:871-3.
21. Eldh J, Boeryd B, Peterson LE. Prognostic factors in cutaneous malignant melanoma in Stage I. Scand J Plast Reconstr Surg 1978;12:243-55.
22. Van der Esch EP, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981;48: 1668-73.
23. Prade M, Bognel C, Charpentier P, Gadenne C, Duvillard P, Sancho-Garnier H, et al. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 239 cases. Am J Dermatopathol 1982;4:411-2.
24. Hacene K, Le Doussal V, Brunet M, Lemoine P, Guerin P, Hebert H. Prognostic index for clinical stage I cutaneous malignant melanoma. Cancer Res 1983;43:2991-6.
25. Sondergaard K, Schou G. Survival with primary cutaneous melanoma evaluated from 2012 cases. Virchows Arch A Pathol Anat Histopathol 1985;405:179-85.
26. Kopf AW, Gross DF, Rogers GS, Rigel DS, Hellmann LJ, Levenstein M, et al. Prognostic index for malignant melanoma. Cancer 1987;59:1236-41.
27. Ronan SG, Han MC, Das Gupta TK. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol 1988;15:558-65.
28. Clark WH Jr., Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
29. Vollmer RT. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989;24:383-407.
30. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population based study. Cancer 1996;78:427-32.
31. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997;24(Suppl 4):S4-2-7.
32. Suter L, Bröcker EB, Brüggen J, Ruiter DJ, Sorg C. Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies. Cancer Immunol Immunother 1983;16: 53-8.
33. Suter L, Bröcker EB, Ostmeier H, Schumann J, Sorg C. Metastatic human melanoma. Phenotypic heterogeneity and antigen expression in relation to the clinical status. J Cancer Res Clin Oncol 1989;115:459-64.
34. Klein CE, Steinmayer T, Kaufmann D, Weber L, Bröcker EB. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991;96:281-4.
35. Vennegoor C, Hageman P, van Nouhuijs H, Ruiter DJ, Calafat J, Ringens PJ, et al. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol 1988;130: 179-92.
36. Holzmann B, Johnson JP, Kaudewitz P, Riethmüller G. In situ analysis of antigens on malignant and benign cells of the melanocytic lineage. Differential expression of two surface molecules gp 75 and p 89. J Exp Med 1985;161:366-77.
37. Johnson JP, Stade BG, Hupke U, Holzmann B, Riethmüller G. The melanoma-progression- associated antigen P 3.58 is identical to the intercellular adhesion molecule ICAM-1. Immunobiology 1988;178:275-84.
38. Carrel S, Accolla RS, Carmagnola AL, Mack JP. Common human melanoma-associated antigens detected by monoclonal antibodies. Cancer Res 1980;40:2523-8.
39. Combaret V. Production d'anticorps monoclonaux anti-melanoma [Ph.D. thesis]. Lyon, France: University Claude Bernard, 1984.
40. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;75:2492-8.
41. Sobin LH, Wittekind C, editors. UICC TNM classification of malignant tumors. 5th ed. Berlin: Springer-Verlag, 1997.
42. Huang X, Soong S, McCarthy WH, Urist MM, Balch CM. Classification of localized melanoma by the exponential survival trees method. Cancer 1997;79:1122-8.
43. Büttner P, Garbe C, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499-506.
44. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15: 1039-51.
45. American Joint Committee on Cancer: Manual for staging of cancer. 4th ed. Philadelphia, PA: Lippincott, 1992:143-8.
46. Cochran AJ. Method for assessing prognosis in patients with malignant melanoma. Lancet 1968;2:1062-4.
47. Drzewiecki KT, Frydman H, Kragh Andersen P, Poulsen H, Ladefoged C, Vibe P. Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982. Cancer 1990;65:362-6.
48. Heenan PJ, English DR, Holman CDJ, Armstrong BK. Survival among patients with clinical Stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/ 1976 and in 1980/81. Cancer 1991;68:2079-87.
49. Soong S-J, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191-5.
50. Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigel DS, Friedman RJ, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992;26:429-40.
51. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlöf B, Ringborg U, Rutquist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994;73:2324-32.
52. Thörn M, Pontén F, Bergström R, Sparén P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.
53. Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin Proc 1997;72:356-61.
54. Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R, et al. Predicting ten year survival of patients with primary cutaneous melanoma. Corroboration of a prognostic model. Cancer 1997;80:1426-31.
55. Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995;75:2484-91.
56. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975 and 1985. Prognostic factors and histologic correlations. Cancer 1997;79:275-83.
57. De las Heras ME, Gonzàles S, Alvarez I, Ledo A. Update in prognostic model for melanoma. Australasian J Dermatol 1997;38(Suppl 2):161.
58. MacKie RM, Carfrae DC, Cochran AJ. Assessment of prognosis in patients with malignant melanoma. Lancet 1972;2: 455-6.
59. Worth AJ, Gallagher RP, Elwood JM, Yang PC, Lamb C, Spinelli JJ, et al. Pathologic prognostic factors for cutaneous malignant melanoma: the western Canada melanoma study. Int J Cancer 1989;43:370-5.
60. Karjalainen J, Eskelinen M, Kosma V-M, Lipponen P, Tuominen L, Alhava E. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma. Anticancer Res 1992;12:1507-11.
61. Talve L, Kainu J, Collan Y, Ekfors T. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary melanoma of the skin. Pathol Res Pract 1996;192:825-33.
62. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
63. MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 1995;71: 173-6.
64. Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Kombinierter prognostischer Index zur Bestimmung des Metastasierungsrisikos primärer maligner Melanome. Verh Dtsch Ges Pathol 1997;81:736.